ES2673028T3 - Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas - Google Patents

Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas Download PDF

Info

Publication number
ES2673028T3
ES2673028T3 ES11847833T ES11847833T ES2673028T3 ES 2673028 T3 ES2673028 T3 ES 2673028T3 ES 11847833 T ES11847833 T ES 11847833T ES 11847833 T ES11847833 T ES 11847833T ES 2673028 T3 ES2673028 T3 ES 2673028T3
Authority
ES
Spain
Prior art keywords
genes
trinucleotide repeats
selective reduction
prolonged
harmful activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11847833T
Other languages
English (en)
Inventor
Tzu-Hao Cheng
Chia-Rung Liu
Tzu-Han Wang
Stanley N. Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Yang Ming Chiao Tung University NYCU
Leland Stanford Junior University
Original Assignee
National Yang Ming Chiao Tung University NYCU
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Yang Ming Chiao Tung University NYCU, Leland Stanford Junior University filed Critical National Yang Ming Chiao Tung University NYCU
Application granted granted Critical
Publication of ES2673028T3 publication Critical patent/ES2673028T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Un agente para el uso en la modificación de la progresión en un sujeto de una enfermedad que surge de un gen que contiene un dominio de repeticiones de trinucleótidos prolongadas mutantes, en el que la administración al sujeto de una cantidad eficaz del agente reduce de manera selectiva una actividad transcripcional mediada por SPT4, para reducir de manera selectiva la actividad perjudicial del gen para modificar la progresión de la enfermedad en el sujeto.
ES11847833T 2010-12-10 2011-12-08 Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas Active ES2673028T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TW99143336 2010-12-10
US13/110,494 US8569254B2 (en) 2010-12-10 2011-05-18 Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
US201161513970P 2011-08-01 2011-08-01
PCT/US2011/063997 WO2012078906A2 (en) 2010-12-10 2011-12-08 Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes

Publications (1)

Publication Number Publication Date
ES2673028T3 true ES2673028T3 (es) 2018-06-19

Family

ID=45528877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11847833T Active ES2673028T3 (es) 2010-12-10 2011-12-08 Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas

Country Status (7)

Country Link
US (6) US8569254B2 (es)
EP (2) EP2463372B1 (es)
JP (1) JP5769084B2 (es)
ES (1) ES2673028T3 (es)
TR (1) TR201808029T4 (es)
TW (1) TWI430812B (es)
WO (1) WO2012078906A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569254B2 (en) 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
AU2016270297B2 (en) 2015-05-29 2019-12-12 National Yang-Ming University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
JP7089763B2 (ja) * 2015-10-05 2022-06-23 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ トリヌクレオチドリピート伸長が関与する遺伝的疾患の予防または治療における一本鎖アンチセンスオリゴヌクレオチドの使用
AU2018286393A1 (en) * 2017-06-15 2020-01-30 College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation Genome editing system for repeat expansion mutation
EP3641758A4 (en) * 2017-06-19 2021-03-17 The Board of Trustees of the Leland Stanford Junior University Compounds for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2019141279A1 (en) * 2018-01-22 2019-07-25 Taiwan Strategics Intellectual Property Co. Ltd. Method to enhance the transcription regulation of SUPT4H on genes containing repetitive nucleotide sequences
US20210238226A1 (en) * 2018-05-22 2021-08-05 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6174670B1 (en) 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
EP0877600B1 (en) 1996-08-09 2003-10-22 Alcon Manufacturing Ltd. Preservative systems for pharmaceutical compositions containing cyclodextrins
US6376257B1 (en) 1997-04-24 2002-04-23 University Of Rochester Detection by fret changes of ligand binding by GFP fusion proteins
AU6095000A (en) 1999-07-13 2001-01-30 Whitehead Institute For Biomedical Research Generic sbe-fret protocol
EP1224199A1 (en) 1999-10-26 2002-07-24 Deltagen, Inc. Transgenic mice containing trp gene disruptions
CA2426479C (en) 2000-11-16 2007-08-07 F. Hoffmann-La Roche Ag Dye pair for fluorescence resonance energy transfer (fret) measurements
US20050277133A1 (en) * 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
AU2003282877B9 (en) * 2002-09-25 2011-05-12 University Of Massachusetts In Vivo gene silencing by chemically modified and stable siRNA
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
WO2004041838A1 (en) 2002-11-01 2004-05-21 University Of Massachusetts Regulation of transcription elongation factors
ATE394677T1 (de) 2002-11-07 2008-05-15 Univ Erasmus Fret proben und verfahren zur erkennung aufeinander einwirkeneden moleküle
ES2485848T3 (es) 2003-09-12 2014-08-14 University Of Massachusetts ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
US8680063B2 (en) * 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
WO2006105038A2 (en) 2005-03-25 2006-10-05 The Uab Research Foundation Methods of altering gene expression and methods of treatment utilizing same
EP1866443A4 (en) 2005-04-04 2009-04-08 Blueshift Biotechnologies Inc SCREENING USING POLARIZATION ANISOTROPY FOR FRET EMISSIONS
WO2007022470A2 (en) * 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
US7375190B2 (en) * 2006-09-19 2008-05-20 National Yang-Ming University Recombinant protein and method of screening for agents that modulate polypeptide aggregation
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
NZ599032A (en) * 2009-09-11 2014-09-26 Isis Pharmaceuticals Inc Modulation of huntingtin expression
WO2011097641A1 (en) * 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
US8569254B2 (en) * 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same

Also Published As

Publication number Publication date
JP5769084B2 (ja) 2015-08-26
WO2012078906A3 (en) 2012-10-04
US9226935B2 (en) 2016-01-05
US9637741B2 (en) 2017-05-02
JP2012125240A (ja) 2012-07-05
EP2463372B1 (en) 2015-09-02
US20130317088A1 (en) 2013-11-28
TR201808029T4 (tr) 2018-06-21
US10760077B2 (en) 2020-09-01
WO2012078906A2 (en) 2012-06-14
US20120149754A1 (en) 2012-06-14
TWI430812B (zh) 2014-03-21
US8569254B2 (en) 2013-10-29
TW201223545A (en) 2012-06-16
US9862947B2 (en) 2018-01-09
EP2705151A4 (en) 2014-10-08
EP2463372A1 (en) 2012-06-13
US9211303B2 (en) 2015-12-15
EP2705151B1 (en) 2018-03-21
US20160152978A1 (en) 2016-06-02
US20130331437A1 (en) 2013-12-12
US20180171336A1 (en) 2018-06-21
EP2705151A2 (en) 2014-03-12
US20160116456A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
ES2673028T3 (es) Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas
BR112013021509A2 (pt) composições para cuidado pessoal
BR112013019702A2 (pt) composições dentais compreendendo agente de adição-fragmentação etilenicamente insaturado.
MX382405B (es) Método para suministrar un agente activo.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
DOP2012000245A (es) Composiciones sólidas
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
PL2811998T3 (pl) Pasożytobójcze doustne kompozycje weterynaryjne obejmujące ogólnoukładowo działające środki aktywne, sposoby oraz ich zastosowania
NI201600071A (es) Compuestos de inhibidor de autotaxina
UA112086C2 (uk) Гербіцидні композиції, що включають хлорацетаміди
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
PE20171763A1 (es) Composiciones y metodos para inhibir la expresion del gen hao1 (hidroxiacido-oxidasa 1 (glicolato-oxidasa))
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
EA201591401A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MX2013002058A (es) Composicion de tratamiento para cabello.
PH12013501481A1 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
AR093939A1 (es) Composiciones que comprenden vortioxetina y donepezil
AR086689A1 (es) Auxiliar de la formulacion para la desinfeccion de semillas
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
BR112013019924A8 (pt) Composições para cuidado oral
CL2015001180A1 (es) Combinacion farmaceutica que comprende un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol o un medicamento para el tratamiento de trastornos cognitivos seleccionado de neurolepticos, antidepresivos, anticonvulsivos o una combinacion de los mismos.